The Department of Neurology and Neurological Sciences at Stanford University School of Medicine, together with multiple academic medical centers and one industry partner (Medtronic) across the US, ...

Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...

The FDA approved Medtronic's BrainSense Adaptive DBS for Parkinson's, offering personalized therapy through automatic adjustments to patients' needs. The ADAPT-PD trial validated aDBS's safety and ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

An Ohio music conductor is using deep brain stimulation to combat his Parkinson’s disease. Rand Laycock, 70, the director and conductor of a symphony orchestra, was diagnosed just before his 60th ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025 ...

On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...

The FDA approved adaptive deep brain stimulation (DBS) technology (BrainSense adaptive DBS and BrainSense electrode identifier) for people with Parkinson's disease, Medtronic announced Monday. Like ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation approach to ...